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cardiovascular morbidity, and in itself is an in‑
dependent risk factor for cardiovascular disease.2 
Endothelial dysfunction caused by imbalance 
of vasoactive molecules, oxidative stress, and 
INTRODUCTION Cardiovascular disease is 
the primary cause of morbidity, mortality, and 
years of life lost in Poland.1 Chronic kidney 
disease (CKD) is frequently complicated with 
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ABSTRACT
BACKGROUND Chronic kidney disease is linked to cardiovascular morbidity; therefore, relevant biomarkers 
are widely investigated.
AIMS We aimed to assess the relationship between nitric oxide (as measured by its metabolites, NOx), 
a key endothelial molecule, with markers of endothelial dysfunction, inflammation, antioxidant status, 
and mineral disorders as well as histologically assessed vascular calcification in uremic and hemodialysis 
patients with chronic kidney disease.
METHODS Plasma and serum samples were obtained from 62 patients with renal failure. NOx was 
assessed by the Griess method, while the other biomarkers were measured by the immunoenzymatic 
assay. Morphological analysis of arterial calcification was performed in a blinded, semiquantitative 
manner. Common carotid intima ‑media thickness and atherosclerotic plaques were assessed by 
ultrasonography.
RESULTS In the simple analysis, NOx levels correlated positively with the parameters of renal function, 
mineral metabolism, endothelial injury, and inflammation. NOx predicted carotid intima ‑media thickness 
in simple (P = 0.014) and multiple analysis (P = 0.036) adjusted for the Framingham risk score, C ‑reactive 
protein, serum creatinine, and parathormone. The occurrence of atherosclerotic plaques in the common 
carotid artery was correlated with higher NOx concentrations (P = 0.021).
CONCLUSIONS In chronic renal failure, NOx is associated with surrogate markers of atherosclerosis, even 
after adjustment for traditional cardiovascular risk factors, inflammation, and renal function, but not with 
the presence or grade of medial arterial calcification. Endothelial injury, inflammation, and mineral metabolism 
markers are associated with NOx levels, though a causal link requires further study.
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of our previous publications.8 We also estimat‑
ed that the inclusion of 60 patients allows for 
90% power to detect a correlation of moderate 
strength (rho = 0.4) at the significance level of 
0.05. All patients provided written and informed 
consent prior to their recruitment. The Bioeth‑
ics Committee of the Jagiellonian University ap‑
proved the study.
Imaging Ultrasonography was performed 
using the  Acuson 128 XP/10 system (Acu‑
son Corp., Mountain View, California, United 
States). An experienced, blinded operator ex‑
amined common carotid artery intima ‑media 
thickness (CCA‑IMT) bilaterally, using a linear 
5/7 MHz probe in B mode. Assessment at 2 fixed 
(predefined) locations, respectively, 0.5 cm and 
2 cm below CCA bifurcation on each side was 
performed during diastole. Data are reported 
as arithmetic means for both arteries in each 
patient. CCA ‑IMT measurements were taken 
outside the locations of possible atherosclerotic 
plaques. The atherosclerotic carotid plaque was 
defined as an echoic focal structure protruding 
into the lumen or focal wall thickening which is 
at least 50% greater than that of the surround‑
ing vessel and is clearly different from the sur‑
roundings. No qualitative and quantitative anal‑
ysis of atherosclerotic plaques was used.
Biochemistry On the morning preceding 
the surgical procedure, patients underwent 
a complete medical examination. Shortly af‑
terwards, following an overnight fast, venous 
blood was drawn from all patients and samples 
of plasma and serum were collected.
Specimens were kept at –70ºC until anal‑
ysis performed within 3 months. Plasma for 
biochemical analysis of oxidative activity was 
stored under recommended operating proce‑
dures; protected from light exposure, positioned 
on ice, centrifuged in a 2‑hour time frame, al‑
iquoted, and kept at –30ºC for up to 1 month. 
Antioxidant capacity of plasma was assessed by 
a previously described method based on scav‑
enging of 2,2‑diphenyl‑1‑picrylhydrazy (DPPH).9 
NOx were determined using the Griess assay, as 
reported previously6: a reaction in which sulfa‑
nilamide and N (1‑naphthyl)‑ethylenediamine 
dihydrochloride in acidic medium (phosphoric 
acid) in combination with nitrates gives the azo 
dye, with maximum absorption at 540 nm. 
Spectrophotometric measurements were per‑
formed using a microplate reader, the Polar Star 
Omega (BMG Labtech, Ortenberg, Germany).
In all patients, selected biochemical param‑
eters were measured, including creatinine, in‑
tact parathyroid hormone (iPTH), total calci‑
um (Ca) and phosphate (Pi), high ‑sensitivity 
C ‑reactive protein (hs‑CRP), interleukin 6 
(IL‑6), PTX3, soluble tumor necrosis factor re‑
ceptor 2 (sTNFR2), fibroblast growth factor 23 
inflammation3,4 is one of the initial events and 
an indicator of vascular pathology in cardiovas‑
cular complications of CKD. Impaired nitric ox‑
ide (NO) synthesis is a hallmark of vascular dis‑
ease5; however, NO is highly reactive and has to 
be assessed indirectly through its relatively sta‑
ble biologic metabolites (NOx), nitrite and ni‑
trate, by a modified Griess assay.6 Nitric oxide 
homeostasis plays a crucial role in the patholo‑
gy of the cardiovascular system.7 The offending 
processes in vascular injury are complex in CKD, 
therefore, establishing the interplay between 
disease ‑driving pathways (through a purport‑
ed relationship between respective biomark‑
ers) is important to develop a risk model for 
this population.
We examined the relationship between NOx 
and surrogate parameters of vascular disease 
as well as biochemical indicators of endothelial 
impairment, inflammation, antioxidant status, 
and mineral bone disease in uremic and hemo‑
dialysis patients with end ‑stage renal disease.
METHODS Patients The study population 
included consecutive patients with advanced 
CKD from a convenience sample at our univer‑
sity center. Sixty ‑two patients fulfilled the pre‑
defined inclusion criteria, namely, stage 5 CKD 
and planned first ‑time arteriovenous fistula 
(AVF) procedures. There were 35 men and 27 
women with a mean (SD) age 63 (16) years. Clin‑
ical, imaging, biochemical, and morphological 
data were gathered in a cross ‑sectional fashion, 
and analyzed for 20 pre dialysis and 42 hemo‑
dialysis patients. Our reference population (for 
NOx measurements) included 44 healthy sub‑
jects (24 men and 20 women) with a mean (SD) 
age of 61 (10) years, mean (SD) body mass index 
of 27.2 (5.6) kg/m², and mean (SD) creatinine lev‑
el of 86 (16) µmol/l. This study is part of a con‑
cluded research initiative, and follows the design 
WHAT’S NEW?
Chronic kidney disease, particularly its advanced stages, is connected with 
severe vascular impairment and the associated deleterious sequelae. Both 
atherosclerosis and medial arterial calcification are processes that have been 
linked to clinical outcomes in renal failure populations. Recently, cardiovascular 
risk models have been developed; however, the idea of a biomarker panel 
dedicated for chronic kidney disease has only been partially explored. 
The present study provides an overview of new and established biomarkers 
of processes involved in vascular disease (ie, inflammation, mineral and bone 
disorder, endothelial injury), which is accompanied by ultrasonography 
assessments and semiquantitative morphological investigations on artery 
samples. This study of the relationships between these markers and/or 
mediators provides insight into the unique interplay occurring in chronic kidney 
disease, which is shown in the uremic and hemodialysis populations. Our data 
may serve as a benchmark for future studies that could aim to establish 
a cardiovascular risk model tailored to chronic renal failure.
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Statistical analysis Numbers of patients (per‑
centage of the group) are reported for categories 
and mean (SD) or median (interquartile range) 
for continuous variables, in accordance with sam‑
ple distribution (assessed with the Shapiro–Wilk 
test). Contingency tables were analyzed using 
the χ2 test. Comparisons between the groups 
were done with the t test or the Mann–Whit‑
ney test. Simple correlations were analyzed us‑
ing the Pearson correlation coefficient, after log 
transformation of right ‑skewed variables. Multi‑
ple linear regression model was calculated using 
the prespecified predictors associated with car‑
diovascular risk, that is, the Framingham risk 
score, serum CRP, iPTH, and creatinine concen‑
trations. A P value of less than 0.05 was consid‑
ered significant. The Statistica 10 software (Stat‑
Soft, Tulsa, Oklahoma, United States) was used 
for computations.
RESULTS There were no differences in demo‑
graphic and cardiovascular risk factors, includ‑
ing smoking status and an established index of 
cardiovascular risk, in the recruited popula‑
tion of uremic (predialysis) patients and those 
already on hemodialysis (TABLE 1).10 In patients 
with NOx levels above the median, female sex 
was more common and renal function (serum 
creatinine) was more impaired than in those 
with NOx levels below or equal to the median 
(TABLE 1). This relationship between NOx and kid‑
ney function was further examined as a contin‑
uous variable: log ‑transformed NOx concentra‑
tions correlated positively with log(creatinine) 
(R = 0.32; P = 0.012).
When considering all patients, the median 
(interquartile range [IQR]) NOx concentration 
was 5.40 (4.52–6.99) µmol/l. The median (IQR) 
(FGF‑23), osteopontin, osteoprotegerin, osteo‑
calcin, DPPH, NOx, transforming growth factor 
β1 (TGF ‑β1), and thrombomodulin (TM).
Plasma / serum samples were assessed using 
an enzyme ‑linked immunosorbent assay micro‑
plates and an ELX808 automatic reader (BIO ‑TEK 
Instruments Inc., Winooski, Vermont, United 
States). The following commercial kits were ap‑
plied: IL‑6, pentraxin 3, sTNFR2, TGF ‑β1, TM 
(R&D Systems, Minneapolis, Minnesota, United 
States); osteoprotegerin (BioVendor, Brno, Czech 
Republic); osteopontin (R&D Systems, Minneap‑
olis, Minnesota, United States); osteocalcin (Me‑
tra / Quidel, San Diego, California, United States) 
and FGF‑23 (Immunotopics Int., San Clemente, 
California, United States).
Routine biochemical tests were carried out us‑
ing automatic biochemical analyzers: Hitachi 917 
(Hitachi, Japan) and Modular P (Roche Diagnos‑
tics, Mannheim, Germany). hs‑CRP was assessed 
nephelometrically (Nephelometer BN II, Siemens 
Healthcare Diagnostics, Munich, Germany).
Histology The methodology adopted was de‑
scribed elsewhere.8 Reproducibility of calcifica‑
tion assessment and superior sensitivity of aliz‑
arin red over other histological staining meth‑
ods are discussed therein. In 36 patients (22 on 
hemodialysis and 14 pre dialysis; 16 with NO lev‑
els below or equal to the median and 20 with 
NO levels above the median), radial artery sam‑
ples were collected during AVF surgery. The sam‑
ples were fixed in formalin, washed, frozen, and 
cut into cross ‑sections. The localization and ex‑
tent of calcifications were assessed by 2 indepen‑
dent blinded observers. Microscopic imaging 
was performed using the Olympus DP‑71 digi‑
tal CCD camera coupled to Olympus BX‑50 mi‑
croscope (Olympus, Tokyo, Japan).
TABLE 1 Demographic and clinical characteristics in patients predialysis (uremia) and on hemodialysis with respect to nitric oxide
Variable Hemodialysis 
(n = 42)
Uremia 
(n = 20)
P value NOx ≤median 
(n = 31)
NOx >median 
(n = 31)
P value
Age, y, mean (SD) 61 (18) 67 (12) 0.2 64 (18) 62 (14) 0.4
Male sex, n (%) 24 (57) 11 (55) 0.9 22 (71) 13 (42) 0.02
Hemodialysis, n (%) – – – 20 (65) 22 (71) 0.6
Dialysis therapy duration, mo, median (IQR) 20 (4–48) – – 13 (4–32) 30 (6–64) 0.2
Diabetes, n (%) 13 (31) 8 (40) 0.5 12 (39) 9 (29) 0.3
Dyslipidemia, n (%) 19 (45) 9 (45) 0.9 11 (35) 17 (55) 0.2
Current smoking, n (%) 11 (26) 6 (30) 0.8 11 (35) 6 (19) 0.1
Hypertension, n (%) 34 (81) 19 (95) 0.1 25 (83) 28 (87) 0.6
BMI, kg/m2, mean (SD) 24.6 (3.9) 26.4 (4.6) 0.06 24.5 (5) 24.8 (3.2) 0.8
Framingham risk score, %, median (IQR) 11 (6–22) 13 (8–21) 0.3 14 (6–22) 9 (7–20) 0.2
Serum creatinine, µmol/l, median (IQR) 470 (383–634) 315 (234–405) <0.001 385 (302–488) 454 (361–687) 0.02
Abbreviations: BMI, body mass index; IQR, interquartile range; NOx, nitric oxide (as indirectly measured through its metabolites)
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The markers of inflammation, but not of an‑
tioxidant capacity, were higher among hemo‑
dialysis patients (TABLE 3) as compared to those 
predialysis. No association of NOx levels above 
and below or equal to the median with param‑
eters of inflammation and antioxidant ca‑
pacity was observed (TABLE 3). Log ‑transformed 
NOx concentrations correlated positively with 
log(sTNFR2) (R = 0.28; P = 0.035), suggesting 
a relationship between systemic inflammation 
and NOx changes.
Serum TM was significantly higher in patients 
undergoing hemodialysis and among patients 
with higher NOx levels (TABLE 4). Log ‑transformed 
NOx concentrations correlated positively with 
log(TM) (R = 0.27; P = 0.045).
We further assessed the  relationship be‑
tween NOx and vascular disease surrogate mark‑
ers. In 39 patients who underwent CCA ultra‑
sound, a positive correlation was found between 
log(NOx) and CCA ‑IMT (R = 0.39; P = 0.014 in 
a simple analysis) (FIGURE 1A) and it remained sig‑
nificant after adjustment for the  Framing‑
ham risk score, parameters of renal function, 
NOx did not differ between hemodialysis and 
predialysis patients (5.62 µmol/l [4.53–7.25] vs 
5.10 µmol/l [4.48–6.20], respectively; P = 0.3). 
A comparison to an internal healthy reference 
population revealed that NOx concentrations 
in our study were low (reference population, 
27.73 µmol/l [19.31–76.39]). This is in line with 
a reference benchmark from the literature and 
the original publication from which we adopt‑
ed our method for the Griess reaction.6,11
When comparing uremic and hemodialy‑
sis patients, we observed that FGF‑23, Ca × Pi 
product, and osteopontin were higher in the lat‑
ter group. This might suggest a more adverse 
mineral ‑bone imbalance, as hemodialysis pa‑
tients showed a greater degree of renal impair‑
ment. In patients with higher NOx concentra‑
tions, similarly, Ca × Pi product and FGF‑23 were 
substantially elevated (TABLE 2). When examining 
continuous variables, log ‑transformed NOx con‑
centrations correlated positively with log(iPTH) 
(R = 0.38; P = 0.005), log(Pi) (R = 0.31; P = 0.017), 
log(Ca × Pi) (R = 0.38; P = 0.003), and log(FGF‑23) 
(R = 0.40; P = 0.003).
TABLE 3  Markers of inflammation and antioxidant capacity in predialysis and hemodialysis patients and their respective relationship to nitric oxide
Biomarker Hemodialysis 
(n = 42)
Uremia 
(n = 20)
P value NOx ≤median 
(n = 31)
NOx >median 
(n = 31)
P value
hs‑CRP, mg/dl 9.73 (4.59–22.1) 3.56 (1.59–8.47) 0.02 7.95 (4.59–20.5) 4.80 (1.59–19.80) 0.3
IL‑6, pg/ml 5.58 (2.81–9.25) 3.6 (2.21–5.17) 0.08 5.02 (2.63–9.36) 4.11 (2.24–6.16) 0.4
sTNFR2, µg/ml 16.2 (13.7–20) 11.6 (9.2–15.7) 0.003 14.7 (11–17.9) 15.6 (11.6–20.6) 0.2
PTX, ng/ml 1.85 (1.09–2.69) 0.8 (0.54–1.48) 0.01 1.41 (0.74–2.33) 1.56 (0.89–2.79) 0.7
DPPH scavenging, % 38.9 (33.7–43.4) 35.7 (33.2–45.2) 0.5 37.0 (32.8–43.5) 38.9 (34.7–43) 0.4
NOx, µmol/l 5.62 (4.53–7.25) 5.1 (4.48–6.2) 0.3 4.53 (4.09–4.88) 6.86 (6.20–8.26) –
Data are presented as median (interquartile range).
Abbreviations: DPPH, 2,2‑diphenyl‑1‑picrylhydrazyl; hs‑CRP, high‑sensitive C ‑reactive protein; IL‑6, interleukin 6; PTX, pentraxin; sTNFR2, soluble tumor necrosis factor 
receptor 2; others, see TABLE 1
TABLE 2 Markers of mineral ‑bone imbalance in patients predialysis and on hemodialysis and their respective relationship to nitric oxide levels
Marker Hemodialysis 
(n = 42)
Uremia 
(n = 20)
P value NOx ≤median 
(n = 31)
NOx >median   
(n = 31)
P value
iPTH, pg/ml 278 (164–560) 294 (175–512) 0.9 279 (164–386) 289 (180–705) 0.4
Ca, mmol/l 2.21 (0.17) 2.23 (0.26) 0.6 2.17 (0.16) 2.26 (0.24) 0.1
Pi, mmol/l 1.60 (1.26–2.05) 1.37 (1.18–1.44) 0.06 1.35 (1.17–1.69) 1.56 (1.35–1.96) 0.05
Ca × Pi, mmol2/l2 3.60 (2.75–4.24) 2.94 (2.61–3.03) 0.04 2.88 (2.43–3.59) 3.59 (2.93–4.14) 0.001
FGF‑23, RU/ml 2275 (754–10 558) 465 (280–1120) 0.002 706 (346–2234) 2276 (977–8208) 0.01
Osteopontin, ng/ml 355 (189–588) 213 (159–352) 0.03 282 (179–522) 341 (222–587) 0.2
Osteoprotegerin, pmol/l 8.13 (6.16–10.61) 6.59 (5.12–9.23) 0.1 7.13 (5.61–9.44) 8.37 (5.94–11.49) 0.2
Osteocalcin, ng/ml 51.1 (36.0–84.5) 38.6 (31.4–54.1) 0.09 40.0 (31.4–76.6) 52.7 (37.7–78.8) 0.2
Data are presented as median (interquartile range).
Abbreviations: Ca, calcium; FGF‑23, fibroblast growth factor 23; iPTH, intact parathyroid hormone; Pi, phosphate; others, see TABLE 1
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median (IQR) NOx concentrations 5.84 µmol/l 
(5.05–7.16) as compared with 4.88 µmol/l 
(4.35–5.67) (P = 0.021) (FIGURE 1B). Radial artery 
samples obtained during AVF formation were 
assessed in 36 patients, 14 samples (38%) did not 
reveal any apparent signs of calcification. Among 
the remaining samples, calcifications ranged 
from a few small dispersed concretions (grade 
1) to heavy mineral deposits occupying large ar‑
eas of the vascular wall (grade 4). Irrespective 
of their advancement, calcifications were ob‑
served primarily in the tunica media. However, 
no significant associations were observed be‑
tween NOx concentrations and the presence or 
grade of radial artery calcifications (TABLE 4, FIGURE 2).
DISCUSSION Our main findings include a sur‑
prising positive relationship between NOx 
and surrogates of atherosclerosis, adjusted 
inflammation, and secondary hyperparathyroid‑
ism (TABLE 5). The prevalence of atherosclerotic CCA 
plaques was 2‑fold higher in patients with NOx 
levels above the median (TABLE 4). This is further 
supported by the observation that patients with 
atherosclerotic plaques had significantly higher 
TABLE 4 Parameters of vascular remodeling / disease in pre dialysis and hemodialysis patients and their respective relationship to NOx
Parameter HD (n = 42) Uremia (n = 20) P value NOx ≤ median 
(n = 31)
NOx> median  
(n = 31)
P value
TGF ‑β1, µg/ml, median (IQR) 5.01 (4.02–6.45) 6.19 (4.05–8.64) 0.3 5 (4.02–8) 5.57 (4.10–6.56) 0.9
Thrombomodulin, ng/ml, median (IQR) 18.9 (14.9–24.7) 14.6 (13.5–17.5) 0.007 15.0 (13.4–17.7) 17.6 (14.9–24) 0.02
CCA ‑IMTa, mm, mean (SD) 0.97 (0.15) 0.96 (0.14) 0.9 0.93 (0.15) 0.99 (0.14) 0.2
Atherosclerotic plaque in CCA, n (%)a 11 (48) 5 (31) 0.3 5 (25) 11 (55) 0.04
Radial artery calcificationsb, n (%) 14 (64) 8 (57) 0.7 10 (62) 12 (60) 0.8
a Data available for 39 patients (23 on hemodialysis and 16 predialysis; 20 with nitric oxide levels equal to or lower than the median and 19 with above the median)
b Data available for 36 patients (22 on hemodialysis and 14 pre dialysis; 16 with nitric oxide levels equal to or lower than the median and 20 with above the median)
Abbreviations: CCA ‑IMT, common carotid artery ‑intima media thickness; TGF ‑β1, transforming growth factor β1; others, see TABLE 1
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 FIGURE 1  Association between nitric oxide concentrations and ultrasound findings: common carotid artery ‑intima media thickness (A) and presence 
of atherosclerotic plaques (B)
 Abbreviations: see TABLES 1 and 4
A B
TABLE 5 Multiple linear regression to predict values of the common carotid 
artery ‑intima media thickness
Independent variables β (SE) P value
Log(NOx) 0.34 (0.16) 0.046
Log(Framingham risk score) 0.62 (0.17) 0.002
Log(hs‑CRP) –0.18 (0.16) 0.3
Log(creatinine) –0.01 (0.19) 0.9
Log(iPTH) –0.05 (0.17) 0.8
Abbreviations: see TABLES 1–4
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As such, the mode of ultrasound assessment 
should be kept in mind when comparing across 
studies. Similarly to our findings, a previous 
cross ‑sectional study of patients on peritoneal 
dialysis reported that NOx correlated positive‑
ly with plaques and CCA‑IMT.15 However, re‑
sults obtained in studies on peritoneal dialysis 
are not directly comparable with those concern‑
ing hemodialysis, with dialysis modality itself 
exerting an impact.23 The relationship between 
NOx and CCA‑IMT in hemodialysis is not clear. 
Ocak et al24 recently assessed serum NOx lev‑
els in patients on hemodialysis and with ure‑
mia, reporting higher levels in both groups as 
compared with healthy controls. In the former, 
a significant positive relationship with hs‑CRP 
levels was observed, which substantiated a hy‑
pothesis of an endothelial protective mecha‑
nism in response to inflammation. Diabetes 
and metabolic syndrome have also been asso‑
ciated with higher serum NOx levels,25 though, 
in the present study, we did not observe a direct 
relationship, possibly because of insufficient pa‑
tient sample. In patients with diabetes, high NOx 
levels have been attributed to putative, induced 
nitric oxide synthase (NOS) isoform production 
perpetrated by inflammation, oxidative stress 
and hypoxia.25,26 These processes are also inte‑
gral to CKD, where uremic toxins, inflammation, 
and oxidative stress are the perpetrators of en‑
dothelial injury.4 Progressing CKD and hemodi‑
alysis are associated with an increase in the lev‑
els of inflammatory cytokines, including TNF,27 
which might partly explain the association be‑
tween NOx and thrombomodulin, a marker of 
endothelial injury and dysfunction,28 which is 
released in TNF ‑stimulated inflammatory set‑
tings,29 as well as between NOx and sTNFR2, 
which is an independent marker of mortality 
and cardiovascular risk in CKD.30 Our findings 
highlight the endothelium as the critical setting 
in CKD, and point to the complexity of process‑
es involved in its impairment.
Previous studies in patients with coronary 
artery disease and healthy controls have shown 
that a lower NOx concentration and an increased 
level of asymmetric dimethyl arginine, an en‑
dogenous NOS inhibitor, occur in vascular dis‑
ease.31 Passauer et al32 studied patients under‑
going hemodialysis using an invasive technique, 
reporting impaired NOS and dilatory vascular 
response, while the baseline nitric oxide gener‑
ation was increased. Some conflicting data re‑
ported so far may be due to heterogenous pop‑
ulations and different approaches to nitric ox‑
ide measurements. We hypothesize that the se‑
vere progression of atherosclerosis in the milieu 
of CKD corresponds with an endogenous failing 
response of an increase in NO, which does not 
alter the overall deficiency of NO characteristic 
of CKD,33 as suggested by the low (overall) NOx 
levels observed in our patients.
for potential confounding parameters of re‑
nal function,12 inflammation,13 the Framing‑
ham cardiovascular risk score,14 and secondary 
hyperparathyroidism15 in chronic renal failure. 
Our data may enable an adequate assessment 
of NOx, as a candidate for longitudinal evalu‑
ation in advanced renal disease, where it may 
serve as an indicator of progressing atheroscle‑
rosis. Patients with higher NOx levels showed 
a greater degree of renal impairment and ele‑
vated markers of endothelial injury and phos‑
phate imbalance. This could imply a relation‑
ship with medial arterial calcification, which, 
although prevalent and associated with hard 
outcomes in CKD,16 can occur without a tra‑
ditional cardiovascular risk profile. However, 
NOx levels were not correlated with incidence 
nor grade of medial arterial calcification, indi‑
cating that these processes may be intercorre‑
lated, rather than directly linked. Plasma anti‑
oxidant markers likewise did not differ in pa‑
tients with uremia and on hemodialysis and 
were not affected by NOx levels.
Atherosclerosis is the underlying setting for 
future cardiovascular events, interplaying with 
inflammatory pathways and matrix alterations, 
both of which have become targets of interest.17,18 
Molecular methods (eg, miRNA profiling) hold 
future promise for diagnostics in cardiovas‑
cular conditions, though their clinical appli‑
cations still remain to be fully elucidated.19 To 
date, CCA‑IMT and plaque presence, surrogate 
markers of atherosclerosis, have been estab‑
lished as a useful diagnostic measure to evalu‑
ate cardiovascular risk.20,21 Meta ‑analyses have 
shown that although CCA‑IMT assessments pre‑
dict vascular events, considerable heterogeneity 
may be observed, partially owing to carotid seg‑
ment definition and measurement protocols.22 
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FIGURE 2  Nitric oxide concentrations associated with grades of radial artery calcification. 
Data are shown as median, interquartile range (box), nonoutlier range (whiskers), and outlier (dot).
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Limitations Our study was designed in an ex‑
ploratory manner, and the cross ‑sectional na‑
ture precludes any statements over causality, 
which could be inferred from statistical anal‑
yses. Secondly, it should be noted that a com‑
parison of plasma and serum levels of mark‑
ers may not reflect the relevant biological pro‑
cesses occurring in a local milieu, which also ex‑
tends to associations with morphological and 
imaging findings. The array of biomarkers in‑
vestigated has been well established in the lit‑
erature; however, our data extend these find‑
ings to the spectrum of advanced CKD. While 
several of the molecules of pathogenic signifi‑
cance to CKD are well recognized, their inter‑
action is not fully known. Associated patho‑
physiological pathways in which they are in‑
volved can be interconnected or occur in par‑
allel throughout the course of progressive ne‑
phropathy. The assessment of a highly reactive 
molecule has also limitations, and each meth‑
od holds some inherent drawbacks.34 NOx lev‑
els can be measured in plasma and serum by 
the Griess assay, a simple and rapid method re‑
ported to be reproducible.35,36 It is widely used as 
shown in the literature, though without certain 
methodological considerations it may be inac‑
curate; interference from components of bodi‑
ly fluids (eg, amino acids, proteins, ascorbate), 
and rapid oxidation of nitrite to nitrate by, for 
example, oxyhemoglobin are factors to account 
for.34 Our adopted method6 involves deprotein‑
ization35 and use of nitrate reductase to recov‑
er nitrite. This method is also in line with prior 
studies,25 which have attempted to circumvent 
the influence of diet on NOx levels through in‑
vestigating fasting blood samples, as it has been 
demonstrated that an elevation in plasma NOx 
concentrations following dietary intake returns 
to baseline following 12 hours.37 Our approach 
holds a narrow scope in being limited to assess‑
ments of NOx and DPPH scavenging, as we did 
not assay other components involved in nitro‑
sative stress and / or redox status.
Conclusions We provide data on a large array 
of biomarkers implicated in renal and cardiovas‑
cular pathophysiology and report their relation‑
ship in uremia and hemodialysis. Our findings 
indicate that NOx remains a positive predictor 
of CCA‑IMT, a surrogate atherosclerosis marker, 
even after adjustment for traditional and non‑
traditional confounders in a multiple linear re‑
gression analysis. No evident relationship with 
the presence or grade of medial artery calcifica‑
tion, assessed in a semiquantitative manner, was 
observed. However, the assessment of a highly 
reactive molecule through its biological metabo‑
lites holds several limitations. Considering NOx 
as a potential biomarker in CKD requires valida‑
tion in homogenous populations to account for 
its relationship with comorbidity status.
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